You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
疫苗股普遍造好 騰盛博藥(02137.HK)漲逾11% 開拓(09939.HK)三天累飆46%
繼默克(MRK.US)後,美國另一間藥廠輝瑞(PFE.US)上週五發布研發新冠口服藥臨牀試驗療效顯着。然而,於本港上市疫苗股於本週一急跌至低位均見承接。尤其是開拓藥業-B(09939.HK)繼週一收復曾急跌17%至33元逾半年低位大部分失地後,股價掉頭連升第三天,今天高開早段曾回吐49.05元拒絕再下,掉頭升破50天線(55.46元),最高見59.5元(暫受制百天線60.95元),現報57.35元,急漲16%,較週一收市價39.3元更累漲46%;成交533萬股。 騰盛博藥-B(02137.HK)繼本週一急跌至17.3元上市新低喘定後,股價也反覆回升,今天高見21.8元,現報21.5元,回升逾11%。藍籌藥明生物(02269.HK)繼週一挫至92.05元逾七個月低喘定後,股價也掉頭連升第三天,今天挑戰10天線(106.46元),最高見107.2元,現報106元,反覆續升1.9%。 然而,復星醫藥(02196.HK)繼週一低見32.55元獲承接,股價掉頭兩連升受制50天線(41.5元)後,今天曾回吐至37.75元,暫守穩10天及20天線(36.8-37.67元),現報38.05元,回吐5.2%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account